

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AMNEAL PHARMACEUTICALS, LLC,
Petitioner

v.

HOSPIRA, INC.,
Patent Owner

Inter Partes Review No. IPR2016-01578
Patent 8,338,470

DECLARATION OF DR. ROBERT LINHARDT

TABLE OF CONTENTS

I.	BACKGROUND AND QUALIFICATIONS.....	1
II.	LEGAL UNDERSTANDING.....	2
	A. Level of a Person of Ordinary Skill in the Art.....	3
	B. Claim Construction	3
	C. Anticipation.....	4
	D. Obviousness.....	5
III.	BACKGROUND OF THE TECHNOLOGY.....	8
	A. State of the Art	8
	B. Subject Matter of the Patents	10
IV.	CLAIM CONSTRUCTION	14
	A. Level of a Person of Skill in the Art	14
	B. “Ready to Use”.....	15
	C. “Dexmedetomidine”	17
V.	SUMMARY OF THE PRIOR ART.....	18
	A. 2010 Label.....	18
	B. Palmgren.....	18
	C. Giorgi.....	21
	D. Eichhorn	22
	E. Lavoisier.....	24
VI.	OPINIONS.....	24
	A. A Ready to Use Dexmedetomidine Composition Would Not Have Been Obvious to a POSA Based on the Prior Art as of January 4, 2012	24

1.	A Ready to Use Dexmedetomidine Composition Would Not Have Been Obvious to a POSA Based on the 2010 Label	26
2.	Dr. Cain’s Stored Dilutions of Concentrated Precedex [®] Are Not “Ready to Use” Dexmedetomidine Compositions	35
3.	It Would Not Have Been Obvious to a POSA on January 4, 2012 to Make a Ready to Use Dexmedetomidine Composition Based on Giorgi and/or Eichhorn	39
B.	It Would Not Have Been Obvious to a POSA as of January 4, 2012 to Store a Ready to Use Dexmedetomidine Formulation in a Sealed Glass Container	45
1.	It Would Not Have Been Obvious to a POSA to Store a Ready to Use Dexmedetomidine Composition in a Sealed Glass Container Based on the 2010 Label	47
2.	It Would Not Have Been Obvious to a POSA to Store a Ready to Use Dexmedetomidine Composition in a Sealed Glass Container Based on Palmgren.....	52
3.	It Would Not Have Been Obvious to a POSA on January 4, 2012 to Store a Ready to Use Dexmedetomidine Composition in a Sealed Glass Container	58
4.	The Results Described in the Wu Declaration Would Have Been Surprising to a POSA on January 4, 2012	64
VIII.	CONCLUSION.....	67

LIST OF EXHIBITS

Exhibit	Document
1007	2010 Precedex® Label (“the 2010 Label”).
1013	FDA Memorandum by Cynthia G. McCormick, M.D., dated November 30, 1999. (“the McCormick FDA Memorandum”).
1015	Giorgi et al., International Journal for Quality in Health Care, Vol. 22, No. 3, 170-178 (2010) (“Giorgi”).
1016	Eichhorn, The Official Journal of the Anesthesia Patient Safety Foundation, Spring 2010 (“Eichhorn”).
1017	Palmgren, European Journal of Pharmaceutics and Biopharmaceutics, June 29, 2006 (“Palmgren”).
1018	Lavoisier Documents; Lavoisier Sodium Chloride Product Sheet, June 2009 (“Lavoisier”).
1019	FDA Memorandum by Bob A. Rappaport, M.D., dated November 5, 1999. (“the Rappaport FDA Memorandum”).
1025	Packaging Drugs and Pharmaceuticals, Wilmer A. Jenkins and Kenton R. Osborn, 1993.
1026	“Pharmaceutical dosage forms, parenteral medications” edited by Kenneth E. Avis, et al. 2nd Edition, p. 161, 1992.
1027	“Sterile Pharmaceutical Packaging: Compatibility and Stability” Y. John Wang and Yie W. Chien, p. 16, 1984.
1028	Paula Youngberg Webb, et al. “The Keys to RTU Parenterals,” Pharmaceutical Formulation & Quality, Vol. 11, No. 5, p. 40, September 2009.
1044	“Injectable medicines,” WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, http://whocc.goeg.at/Glossary/PreferredTerms .

1057	Declaration of Huailiang Wu, U.S. Application No. 13/541,524 (“the Wu Declaration”).
2001	U.S. Patent No. 8,242,158 (“the ’158 Patent”).
2002	U.S. Patent No. 8,338,470 (“the ’470 Patent”).
2003	U.S. Patent No. 8,455,527 (“the ’527 Patent”).
2004	U.S. Patent No. 8,648,106 (“the ’106 Patent”).
2008	“Guidance for Industry: Drug Stability Guidelines,” FDA Center for Veterinary Medicine, p. 26, Dec. 2008.
2009	“Guidance for Industry: Q1A (R2) Stability Testing of New Drug Substances and Products,” FDA Center for Drug Evaluation and Research, p. 10, Nov. 2003.
2011	Speaker, T.J. et al., “A Study of the Interaction of Selected Drugs and Plastic Syringes,” PDA J Pharm Sci and Tech, 45:212-217 (1991).
2012	Kaur, M. et al., “Current role of dexmedetomidine in clinical anesthesia and intensive care,” Anesth Essays Res. 2011 Jul-Dec., 5(2): 128-133.
2013	Ecoflac® Plus Brochure, B Braun.
2014	P. Donyai and G. Sewell, “Physical and chemical stability of paclitaxel infusions in different container types,” J. Oncol. Pharm. Practice, 12, pp. 211-222 (2006).
2015	Anes, J. et al., “Use of Plastics for Parenteral Packaging,” Pharmaceutical Dosage Forms: Parenteral Medications Volume 1, 2d Ed. (1992).
2016	Webb, P. et al., “Ensure Safety, Efficacy of Ready-to-Use IV Drug Products,” PFQ Vol. 11, No. 6, Oct./Nov. 2009.
2017	“Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics,” FDA Center for Drug Evaluation and Research, pp. 7-10, May 1999.
2018	Dahlstrom, M. et al., “Impact of polymer surface affinity of novel antifouling agents,” Biotechnol Bioeng. 2004 Apr 5;86(1):1-8.
2024	Label for 0.9% w/v Sodium Chloride Intravenous Infusion BP, B. Braun Melsungen AG, Dec. 2010, available at https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Sodium_Chloride_0-9_DR_1319972870952.pdf .

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.